Similarly, treatment with a bromodomain and extra-terminal motif (BET) protein inhibitor (BETi) suppresses EVI1 expression and reduces the viability of EVI1 overexpressing AML cells [60]. This evidence concerns the gene MECOM and acute myeloid leukemia.